At the IASLC World Conference on Lung Cancer meeting, Boehringer Ingelheim hosted a symposium and a number publications related to our products were presented to highlight our advances in the treatment of lung cancer.
An international faculty of experts discussed clinical considerations for sequencing EGFR TKIs, for preventing and managing brain metastases in patients with EGFR mutation-positive NSCLC, and for maximising the potential of TKIs for SqCC of the lung.
Please see below for symposium presentation downloads.
Please see downloadable versions below.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: September 2018